

NeuroStar[®]

TAP INTO A NEW POSSIBILITY

for mental health


- FDA-cleared
- Safe and effective
- Non-drug and non-invasive
- Covered by most insurance

Give your patients with MDD, OCD, Anxious Depression, and Adolescent Depression (15-21) proven relief that lasts.



Treat Depression at the Source

NeuroStar TMS (Transcranial Magnetic Stimulation) goes right to the source of depression – the brain. It is a non-invasive, non-drug treatment that uses focused magnetic pulses to “wake up” those areas, and help patients’ brain work the way it should.^{1,2} It’s like physical therapy for the brain.



Actual PET Scans of Adult Brains


Source: Mark George, MD, Biological Psychiatry Branch, Division of Intramural Research Programs, NIMH 1993.

The #1 Physician Recommended TMS Treatment

Since 2008, NeuroStar has been used over 6.9 million times in over 188,000 patients, proving to be safe and effective for adults and adolescents (15-21) with depression.³

Long-Lasting Results

NeuroStar is the only treatment clinically proven to be effective through 12 months in adult treatment-resistant depression (TRD) patients.⁴



Covered by Most Major Insurance Companies

More than **300 million people**³ in the U.S. have insurance that covers NeuroStar®.

Financing options may be available for patients whose treatment is not covered by insurance.



NeuroStar is an Easy, In-Office Experience

Patients are awake and fully alert during treatment.



A session lasts as little as **19 minutes** per day*



Resume normal activities **immediately** after treatment



36 treatment sessions to completion*

Identifying a NeuroStar Candidate

- Has a diagnosis of adult MDD or OCD
- Has a diagnosis of adolescent MDD (15-21)
- Unhappy with current medication therapy
- Has one or more medication failures
- Cannot tolerate medication side effects
- Wishes to avoid antidepressants

Referring a Patient to Greenbrook for NeuroStar TMS is as easy as 1-2-3

1

Identify Candidates

Recommend NeuroStar TMS for patients that meet the treatment criteria.

2

Submit a Referral

Send the completed referral form and relevant patient records to your local Greenbrook center.

3

Coordinate and Stay Updated

Receive patient progress updates and collaborate on follow-up care as needed.

Have Questions?

Your Local Greenbrook Representative is ready to help.

Where to Start

For more information on partnering with Greenbrook Mental Wellness Centers or to refer a patient, please contact us at:

greenbrookproviders.com/refer
or scan here! →



* The NeuroStar Healthcare Provider will determine what is right for the patient.

References:

1. Post A, et al. (2001). J Psychiatric Research, 35:193-215.
2. Liston C, Chen AC, Zebley BD, et al. (2014). Biol Psychiatry, 75(7):517-526.
3. Data on file. Neuronetics, Inc. 2024.
4. Dunner DL, et al. (2014). J Clin Psychiatry, 75(12):1394-1401.
5. Sackeim HA, et al. (2020). J Affect Disord, 277:65-74. Based on a real-world, retrospective study using CGI-S and a sample size of 615 patients.

Adult Indications for Use

The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy System is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

Adolescent Indications for Use

NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of Major Depressive Disorder (MDD) in adolescent patients (15-21).

Important Safety Information

NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients' results may vary.

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).

Visit neurostar.com for full safety and prescribing information.

